Icure Pharmaceutical Incorporation (175250) - Cash Flow Conversion Efficiency

Latest as of March 2025: -0.055x

Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has a cash flow conversion efficiency ratio of -0.055x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.28 Billion ≈ $-2.23 Million USD) by net assets (₩59.43 Billion ≈ $40.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 175250 equity financing ratio to measure how much of total assets are equity-financed.

Icure Pharmaceutical Incorporation - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Icure Pharmaceutical Incorporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 175250 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Icure Pharmaceutical Incorporation Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jiayin Group Inc NASDAQ:JFIN	0.766x
American Creek Resources Ltd V:AMK	-0.114x
NTPM Holdings Bhd KLSE:5066	0.027x
Fortune Minerals Limited TO:FT	0.105x
Samhwa Networks Co. Ltd KQ:046390	0.086x
Playstudios Inc NASDAQ:MYPS	0.024x
Flag Ship Acquisition Corp. Ordinary Shares NASDAQ:FSHP	-0.006x
Fidelix Co. Ltd KQ:032580	-0.050x

Annual Cash Flow Conversion Efficiency for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Icure Pharmaceutical Incorporation stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩60.26 Billion ≈ $40.84 Million	₩-17.05 Billion ≈ $-11.56 Million	-0.283x	-24.75%
2023-12-31	₩59.59 Billion ≈ $40.39 Million	₩-13.52 Billion ≈ $-9.16 Million	-0.227x	-80.30%
2022-12-31	₩89.67 Billion ≈ $60.77 Million	₩-11.28 Billion ≈ $-7.65 Million	-0.126x	+54.07%
2021-12-31	₩95.76 Billion ≈ $64.89 Million	₩-26.23 Billion ≈ $-17.77 Million	-0.274x	-147.68%
2020-12-31	₩112.15 Billion ≈ $76.01 Million	₩-12.40 Billion ≈ $-8.41 Million	-0.111x	-81.49%
2019-12-31	₩97.53 Billion ≈ $66.10 Million	₩-5.94 Billion ≈ $-4.03 Million	-0.061x	+29.34%
2018-12-31	₩84.69 Billion ≈ $57.40 Million	₩-7.30 Billion ≈ $-4.95 Million	-0.086x	-234.63%
2017-12-31	₩17.47 Billion ≈ $11.84 Million	₩1.12 Billion ≈ $758.55K	0.064x	+122.24%
2016-12-31	₩16.94 Billion ≈ $11.48 Million	₩-4.88 Billion ≈ $-3.31 Million	-0.288x	-741.49%
2015-12-31	₩5.96 Billion ≈ $4.04 Million	₩-204.05 Million ≈ $-138.28K	-0.034x	--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21486 Global

#1236 in Korea

Share Price

₩2170.00

Change (1 day)

+0.00%

52-Week Range

₩2170.00 - ₩2170.00

All Time High

₩23730.97